

Manulife Global Fund
Société d'investissement à capital variable
Registered office: 31, Z.A. Bourmicht, L-8070 Bertrange
Grand Duchy of Luxembourg

This document is important and requires your immediate attention. If in doubt, you should seek independent professional advice. The Directors of the Company accept full responsibility for the accuracy of the information contained in this Notice and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief there are no other facts the omission of which would make any statement misleading.

**Clarification to
Notice to Shareholders dated 19 June 2023
in relation to Taiwan Equity Fund
("Notice")**

31 July 2023

Dear Shareholder,

We are writing to you in relation to a notice issued to you on 19 June 2023 ("**Earlier Notice**"), relating to certain changes to the Manulife Global Fund (the "**Company**").

Words and phrases used in this Notice shall, unless otherwise provided, have the same meanings as are ascribed to them in the Earlier Notice.

The Earlier Notice notified you of certain benchmark changes and/or clarifications with effect from 1 August 2023 (the "**Effective Date**"). In particular, the Earlier Notice specified that the name of the existing performance comparison benchmark of Taiwan Equity Fund will be updated from the TSEC TAIEX index to the TSEC TAIEX PR TWD index. You are receiving this Notice because you are an investor of Taiwan Equity Fund.

We would like to take this opportunity to clarify that, with effect from the Effective Date, the name of the performance comparison benchmark of Taiwan Equity Fund will be TSEC TAIEX TR TWD index as opposed to TSEC TAIEX PR TWD index. As such, the details relating to Taiwan Equity Fund set out in the Earlier Notice should be amended as follows:-

Sub-Funds	Current Benchmark Name	Revised Benchmark Name
Taiwan Equity Fund	TSEC TAIEX index	TSEC TAIEX <u>TR</u> PR TWD index

For the avoidance of doubt, the above correction aims at correctly reflecting the name of the existing performance comparison benchmark of Taiwan Equity Fund, and there is no actual change to the benchmark adopted by the Sub-Fund.

General

The correction articulated in this Notice has been reflected in the revised Prospectus of the Company dated August 2023 (the "**Revised Prospectus**"). This Notice should be read in conjunction with the Earlier Notice and the full text of the Revised Prospectus (which contains full and complete information about these changes).

For Hong Kong Shareholders Only: The Revised Prospectus, the Hong Kong Covering Document and the product key fact statement of the Sub-Fund are available during usual business hours on any weekday (Saturdays and public holidays excepted) at the office of the Hong Kong Representative free of charge and are also available at www.manulifefunds.com.hk¹.

Shareholders requiring further information about any of the matters set out in this Notice may contact the Administrator of the Company, Citibank Europe plc, Luxembourg Branch, at telephone number (352) 45 14 14 316 or fax number (352) 45 14 14 850 or the Hong Kong Distributor, Manulife Investment Management (Hong Kong) Limited, at telephone number (852) 2108 1110 or fax number (852) 2810 9510 at any time during normal business hours.

Yours faithfully

Board

For and on behalf of Manulife Global Fund

¹ This website has not been reviewed by the SFC.